Accountability
FDA restricts Johnson & Johnson COVID vaccine for some due to blood clot risk
On Thursday the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 Vaccine.
After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine.
The FDA has determined that the known and potential benefits of the vaccine for the prevention of COVID-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and for individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. (FDA website)
“We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.
“Today’s action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions. We’ve been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA. The agency will continue to monitor the safety of the Janssen COVID-19 Vaccine and all other vaccines, and as has been the case throughout the pandemic, will thoroughly evaluate new safety information.”
A Johnson & Johnson spokesman said in an emailed statement: “Data continue to support a favorable benefit-risk profile for the Johnson & Johnson COVID-19 vaccine in adults, when compared with no vaccine.”
Terry A. Hurlbut has been a student of politics, philosophy, and science for more than 35 years. He is a graduate of Yale College and has served as a physician-level laboratory administrator in a 250-bed community hospital. He also is a serious student of the Bible, is conversant in its two primary original languages, and has followed the creation-science movement closely since 1993.
-
Executive4 days ago
The Hunters Have Now Become The Hunted: Their Cruelties Are Swelling The Ranks Of The People Worldwide!
-
Clergy3 days ago
Why Do The American People Let The Corrupt Media & Politicians Set The Propaganda Narrative – Speak On Their Behalf
-
Constitution4 days ago
CHAPTER 9: Norman Dodd Interview Space Is No Longer the Final Frontier––Reality Is [upcoming release April 2024]
-
Entertainment Today3 days ago
Civil War (2024) – an incomplete prediction
-
Education3 days ago
CHAPTER 10: Objective Reality Is Required for a Free Society Space Is No Longer the Final Frontier—Reality Is [upcoming release May 2024]
-
Human Interest2 days ago
Idaho prepares to defend its abortion ban
-
Executive4 days ago
National Security Implications of Baltimore Bridge Catastrophe
-
Executive4 days ago
California Dems Tout Ties to Criminal Leniency Group